Months after Imfinzi combo flops, AstraZeneca wins NICE endorsement as lung cancer monotherapy - Endpoints News

  1. Months after Imfinzi combo flops, AstraZeneca wins NICE endorsement as lung cancer monotherapy  Endpoints News
  2. AstraZeneca's Imfinzi gets a lift in lung cancer from England's cost watchdogs  FiercePharma
  3. Lung cancer: diagnosis and management: summary of updated NICE guidance  The BMJ
  4. AZ gets NICE nod for 'big advance' Imfinzi in lung cancer  pharmaphorum
  5. NICE green light for Imfinzi in groundbreaking early lung cancer treatment  PMLiVE
  6. View full coverage on Google News


Comments

Popular posts from this blog

A Review of the Etiology and Epidemiology of Bladder Cancer: All ...

Oncology: The disease, dynamics & challenges of market research

Respirology | APSR Respiratory Medicine Journal